Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Cel-Sci Corporation/ 10-K

Annual Report · 10-K

Cel-Sci Corporation

CVMNYSE_AMERICANEQUITYCurrent

Annual Report

Filed Dec 21, 2023Accepted Dec 21, 2023, 4:15 PM ESTCIK 725363Accession 0001654954-23-015877
View company →Permanent SEC source ↗
Share

Company context

We are a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. We are currently focused on the development of the following product candidates and technologies with emphasis on Multikine:

Current securities

CVMNYSE_AMERICAN · EQUITY · Current
Historical securities (1)
CVM.WSNYSE_AMERICAN · WARRANT · Historical · closed Oct 9, 2018

Recent company filings

  1. S-8 filingSep 3, 2026
  2. Submission of Matters to a Vote of Security HoldersAug 17, 2026
  3. 10-Q filingAug 14, 2026
  4. ARS filingJul 2, 2026
  5. DEF 14A filingJul 2, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗